Synpromics is a private company which has grown through ongoing investment from inside and outside the pharma and biotech industry. Initial investment was made by Friends and Family and Scottish Investment Bank, followed by investment from Calculus Capital.

Synpromics, a private company, has raised total funds of £7.4M from Friends & Family, Scottish Investment Bank, and Calculus Capital.

In addition, the company as been supported by numerous grant awards from Scottish Enterprise, InnovateUK and IBioIC, to the value of a further £3.5M of non-dilutive funding.

About Calculus Capital

Calculus Capital logo

Calculus Capital is a specialist in creating and managing private equity funds for individuals. A pioneer in the Enterprise Investment Scheme (EIS) space, Calculus launched the UK’s first HMRC-approved EIS fund in 1999 and has gone on to launch 16 further funds and four VCT offers. Calculus seeks capital appreciation from dynamic, established, private UK companies across a multitude of sectors. Calculus prefers to invest £2m-£5m per company. As at January 2017 it had over £130m of funds under management.

Calculus Capital’s experienced investment team, diligent investment process and ‘hands on’ approach have resulted in an impressive track record of investment success. Calculus has won multiple awards including ‘Best EIS Fund Manager’ at the Growth Investor Awards 2016 and the EIS Association’s ‘Fund Manager of the Year’ Award in 2016, 2015, 2014, 2011 and 2009.

Calculus Capital is authorised and regulated by the Financial Conduct Authority.

To hear from Calculus Capital about why they invest in Synpromics and the growth their investment has enabled, view their recent video.

About the Scottish Investment Bank

Scottish Investment Bank logo

The Scottish Investment Bank (SIB) is the investment arm of Scotland’s main economic development agency, Scottish Enterprise, operating Scotland-wide in partnership with Highlands and Islands Enterprise. It manages a suite of co- investment funds including the Scottish Co-investment Fund and the Scottish Venture Fund, which are partly funded by the European Regional Development Fund (ERDF) and the Scottish Recycling Fund. SIB is the cornerstone investor in the privately-managed Scottish Loan Fund, managed by Maven Capital Partners and an investor in Epidarex Capital’s life sciences fund. SIB’s investment funds support Scotland’s SME funding market to ensure businesses with growth and export potential have adequate access to growth capital. SIB also provide a team of Financial Readiness specialists to help companies prepare for new investment and access appropriate finance.